GlassScriptPhysician profile
Gang Chen
NPI 1417390576
$8,711.52
in general payments reported to CMS, 2019-2025
43 companies · $4,529 in 2025
The $4,529 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.40 · 2020: $169 · 2021: $13.29 · 2022: $279 · 2023: $680 · 2024: $2,991 · 2025: $4,529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,325 · Food and Beverage: $3,790 · Education: $84.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,325.00 |
| Food and Beverage | $3,790.11 |
| Education | $84.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,938.87 | 2022-2025 | Imfinzi, Calquence, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $2,209.07 | 2022-2025 | Opdivo, Opdualag |
| Daiichi Sankyo INC. | $374.80 | 2020-2025 | Enhertu |
| Gilead Sciences, INC. | $243.27 | 2024-2025 | Trodelvy |
| Exelixis INC. | $230.69 | 2024-2025 | Cabometyx |
| Janssen Biotech, INC. | $228.48 | 2024-2025 | Rybrevant, Tecvayli, Talvey |
| Incyte Corporation | $226.77 | 2023-2025 | Monjuvi, Jakafi, Pemazyre |
| Regeneron Healthcare Solutions, INC. | $190.95 | 2023-2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $187.68 | 2020-2025 | |
| Celgene Corporation | $155.46 | 2024-2025 | Reblozyl |
| Merck Sharp & Dohme LLC | $143.14 | 2022-2025 | Keytruda, Lynparza, Reblozyl |
| Eisai INC. | $140.86 | 2022-2025 | |
| Stemline Therapeutics INC. | $131.44 | 2025 | Orserdu |
| Abbvie INC. | $125.33 | 2023-2025 | Venclexta |
| Pfizer INC. | $99.55 | 2019-2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $94.95 | 2023-2025 | Verzenio, Jaypirca |
| Alexion Pharmaceuticals, INC. | $85.98 | 2023-2024 | Ultomiris |
| Aveo Pharmaceuticals, INC. | $84.50 | 2023 | Fotivda |
| Bayer Healthcare Pharmaceuticals INC. | $63.40 | 2025 | |
| Glaxosmithkline, LLC. | $60.97 | 2024-2025 | Jemperli, Zejula |
| Taiho Oncology, INC. | $57.56 | 2024 | |
| Beone Medicines USA, INC. | $53.20 | 2025 | Tevimbra |
| Genzyme Corporation | $52.73 | 2023-2024 | |
| Array Biopharma INC | $48.95 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Janssen Pharmaceuticals, INC | $45.95 | 2020 | |
| Genentech USA, INC. | $42.34 | 2019-2025 | Polivy |
| Seagen INC. | $32.76 | 2021-2023 | Tukysa |
| Astellas Pharma US INC | $29.16 | 2025 | Vyloy |
| Geron Corporation | $28.93 | 2025 | Rytelo |
| Pharmacosmos Therapeutics INC. | $27.35 | 2025 | Monoferric |
| Tolmar, INC. | $27.14 | 2025 | Rubraca, Eligard |
| Pharmaand Gmbh | $27.14 | 2025 | Rubraca |
| Ipsen Biopharmaceuticals, INC | $26.31 | 2025 | Onivyde |
| Ge Healthcare | $25.75 | 2020 | |
| Deciphera Pharmaceuticals INC. | $25.15 | 2024 | Qinlock |
| Morphosys, US INC. | $24.79 | 2023 | Monjuvi |
| Caris Mpi, INC. | $20.68 | 2025 | Mi Cancer Seek |
| Pharmacyclics LLC, An Abbvie Company | $19.45 | 2020 | |
| Agios Pharmaceuticals, INC. | $17.79 | 2020 | |
| Coherus Oncology, INC. | $17.50 | 2024 | |
| Azurity Pharmaceuticals, INC. | $16.42 | 2025 | Danziten |
| Puma Biotechnology, INC. | $15.86 | 2025 | |
| Karyopharm Therapeutics INC. | $12.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gang Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.